Peptide Receptor Radionuclide Therapy [177Lu]Lu-Edotreotide Prolongs PFS in Patients with Advanced, Progressive, Somatostatin Receptor-Positive GEP NETs By Ogkologos - July 28, 2026 45 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COMPETE study Source RELATED ARTICLESMORE FROM AUTHOR Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-Naive/Sensitive Prostate Cancer EMA Recommends Extension of Therapeutic Indications for Cetuximab No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy with Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma MOST POPULAR The team tackling the serious side effects of cancer treatment in... August 19, 2020 Drug Combination May Target the Unique Metabolism of Leukemia Stem Cells December 14, 2018 Here’s Why We’re Building Pet-Friendly Domestic Violence Shelters–And How You Can... October 18, 2021 2025 ESMO Society Award recipients announced August 5, 2025 Load more HOT NEWS EU Cancer Mission and Partners Launch First Cancer Mission Forum for... No OS Benefit in EGFR T790M Advanced NSCLC Treated with Osimertinib... Study Suggests a Link between Stress and Cancer Coming Back Trial Suggests Expanded Role for Blinatumomab in Treating ALL
